MENU

September 2, 2019 (Diclofenac and Dexmedetomidine)

September 2, 2019 (Diclofenac and Dexmedetomidine)

April 1 & 15, 2019 (Rabeprazole, etc.)

June 15, 2019 (Norethistherone, etc.)

November 23, 2018 (Reteplase)

October 3, 2018 (Cinacalcet)

October 03, 2019 (Pantoprazole IV)

October 03, 2019 (Pantoprazole tablet)

September 02, 2019 (Immunoglobulin Normal, Human (IVIG)

May 27, 2019 (Anastrozole, etc.)

December 17, 2018 (Rifapentine)

December 5, 2018 (Levetiracetam, Memantine)

November 2018 (0.9% Sodium Chloride, Tolvaptan)

2019

Medicine/s Name Dosage/s and Strength/s Remarks Issuance
Fentanyl Citrate

•100 mcg, 200 mcg, 300 mcg and 400 mcg sublingual (SL) tablets

 

- Additional dosage form to the currently listed fentanyl citrate 50
micrograms/mL, 2 mL and 10 mL ampule.

- Indication: Management of breakthrough pain in adult patients using opioid therapy
for chronic cancer pain.

- Government list price: 

Php 206.81 per tablet

Department Memorandum no. 2019-0361
Anastrozole

• 1 mg film coated tablet

 

- Recommended for inclusion

- Indication:

a) Adjuvant treatment of post-menopausal women with hormone receptor positive early breast cancer.

b) First line treatment of post-menopausal women with hormone receptor positive or hormone receptor unknown locally
advanced or metastatic breast cancer.

c) Treatment of advanced breast cancer in postmenopausal women with disease progression after tamoxifen therapy.

- Government list price: Lower or equal to the drug price reference index of its alternative under the same drug class, i.e., letrozole, which is Php 83.60 (DPRI 2018).

Department Memorandum no. 2019-0361
Lagundi

• 600 mg/5 mL syrup, 60 mL and 120 mL bottle

 

- Additional dosage strength to the currently listed lagundi 300 mg/5 mL
syrup. This syrup dosage form for adult use has faster onset of action than the tablet
form.

- Government list price: 

652 mg/mL, 50 mL: Php 2,757.36
652 mg/mL, 100 mL: Php 5,083.04
550 mg/mL, 50 mL: Php 2,240.00

Department Memorandum no. 2019-0361
Latanoprost + timolol maleate

• 50 mcg + 5 mg per mL ophthalmic solution, 5 mL
bottle

 

- Recommended for inclusion

- Indication: Reduction of intraocular pressure (IOP) in patients with open-angle glaucoma and ocular hypertension who are insufficiently responsive to topical beta-blockers or prostaglandin analogues.

- Government list price: Php 800.00 per bottle

Department Memorandum no. 2019-0361
Iodixanol

• 652 mg/mL (equivalent to 320 mg iodine) solution for injection, 50 mL and 100 mL vial

• 550 mg/mL (equivalent to 270 mg iodine) solution for injection, 50 mL vial

 

- Recommended for inclusion

- Indication: X-ray contrast medium for use in adult for cardioangiography, conventional cerebral angiography, peripheral angiography, (conventional), abdominal angiography, urography, venography, CT enhancement & studies of the gastrointestinal (GI) tract & for use in children for cardioangiography, urography, CT enhancement & studies of the GI tract. Lumbar, thoracic & cervical myelography. Arthrography & hysterosalpingography.

- Government list price: 

652 mg/mL, 50 mL: Php 2,757.36
652 mg/mL, 100 mL: Php 5,083.04
550 mg/mL, 50 mL: Php 2,240.00

Department Memorandum no. 2019-0287
Hypertonic lactate solution

 

- Recommended for inclusion

- Indication:

(1) Small volume fluid therapy for rapid resuscitation of intravascular volume (hemorrhagic shock, dengue shock, burnt patient, etc.);

(2) prevention of hypovolemia and maintaining stable hemodynamic status (perioperative condition);

(3) as an alternative in the treatment of metabolic acidosis, electrolyte disorder (hyponatremia);

(4) treatment for tissue peripheral edema; reduction of intracranial pressure in traumatic brain injury; and,

(5) source of alternative energy substrate during cell restoration post-ischemia.

- Government list price: Php 683.50 per 250 mL flexy bag

Department Memorandum no. 2019-0287
Famotidine

• 20 mg powder/lyophilized powder for injection, ampule/vial

- Revision in the specifications

Department Memorandum no. 2019-0286
Epinephrine (adrenaline)

• 1 mg/mL, 1 mL ampule (IV, IM, SC) as hydrochloride

- Revision in the specifications

Department Memorandum no. 2019-0251
Bedaquiline fumarate

• 100 mg tablet

- Recommended for inclusion

- Indication: Multi-drug resistant tuberculosis (MDRTB).

- Remarks: For use by the National Tuberculosis Control Program (NTP) of the Department of Health (DOH) only.

Department Memorandum no. 2019-0250
Delamanid

• 50 mg film coated tablet

- Recommended for inclusion

- Indication: Multi-drug resistant tuberculosis (MDRTB).

- Remarks: For use by the National Tuberculosis Control Program (NTP) of the Department of Health (DOH) only.

Department Memorandum no. 2019-0250
Polymixin B Sulfate

• 500,000 Units powder for solution for injection (Intrathecal/IM/IV), 5 mL vial

- Recommended for inclusion

- Indication: Treatment of infections of the blood stream caused by susceptible strains of Pseudomonas aeruginosa. It is likewise indicated in serious infections caused by susceptible strains of the following organisms: Haemophilus influenzae, Escherichia coli, Aerogenes (specifically bacteremia), and Klebsiella pneumoniae (specifically bacteremia)

Department Memorandum no. 2019-0250
Bedaquiline fumarate

• 100 mg tablet

- Recommended for inclusion

- Indication: Multi-drug resistant tuberculosis (MDRTB).

- Remarks: For use by the National Tuberculosis Control Program (NTP) of the Department of Health (DOH) only.

Department Memorandum no. 2019-0250
Neostigmine

• 500 mcg/mL solution for injection (IM/IV/SC), 1 mL ampule

- Recommended for inclusion

Department Memorandum no. 2019-0206
Multivitamins

 

- Revision in the specifications

Department Memorandum no. 2019-0196
Amino Acid Solutions for Infants

•Solution:
Volume: 100 mL

Concentration: 5 - 10 %

Protein: 5 - 10 g including taurine

Calories: 20 — 40 kcal

Electrolytes: none

- Revision in the specifications

Department Memorandum no. 2019-0196
Levetiracetam

250 mg, 500 mg, 750 mg, and 1 g film coated tablet

• 500 mg/5 mL (100 mg/mL) concentrate solution for IV infusion, 5 mL vial

• 100 mg/mL oral solution, 100 mL and 300 mL bottle

- Recommended for inclusion

- Indication: Control of generalized tonic-clonic status epilepticus, particularly in patients whom other anti-convulsants are contraindicated; control of generalized tonic-clonic seizures or focal seizures when oral anti-convulsants cannot be administered.

Department Memorandum no. 2019-0163
Memantine

5 mg and 10 mg film coated tablet

- Recommended for inclusion

- Indication: For dementia, Alzheimer's disease, and vascular dementia

Department Memorandum no. 2019-0163
Rifapentine

150 mg film coated tablet

- Recommended for inclusion

- Indication: For the treatment of latent tuberculosis infection (LTBI).

- Remarks: For use by the National Tuberculosis Control Program (NTP) of the Department of Health.

Department Memorandum no. 2019-0163
Tolvaptan 15 mg tablet

- Recommended for inclusion for the
following FDA-approved indications and usage:

a) Hyponatremia

Tolvaptan is indicated for the treatment of
patients with clinically significant
hypervolemic and euvolemic hyponatremia
(serum sodium < 125 mEq/L or less marked
hyponatremia that is symptomatic and has
resisted con‘ection with fluid restriction).
including those with heart failure, and
Syndrome of Inappropriate Antidiuretic Hormone (SIADH).

Important Limitations:

Patients requiring intervention to raise serum sodium urgently to prevent or to treat serious neurological symptoms should not
be treated with tolvaptan. It has not been established that raising sentm sodium with tolvaptan provides a symptomatic benefit to patients

b) Adjunct Treatment of Volume Overload in Heart Failure

Volume overload in heart failure when adequate response is not obtainedi with other diuretics (e.g., loop diuretics).

Important Limitations:

Tolvaptan should be used in combination with other diuretics, such as loop diuretics, thiazides, and aldosterone antagonists.

Department Memorandum no. 2019-0033
0.9% Sodium Chloride Solution for Irrigation, 1000 mL, (1L) bottle

- Recommended for Inclusion 

- For inclusion as an additional preparation to the currently listed 0.9% Sodium Chloride solution for IV infusion.

Department Memorandum no. 2019-0033